QQuidelOrtho provides in vitro diagnostics (IVD) products, including diagnostic tests and equipment that use immunoassay and molecular testing to detect medical conditions. Its products are used in point-of-care settings, clinical laboratories, and transfusion medicine, serving individual healthcare providers to large institutions. The company develops and manufactures these tests and devices, which run on specialized platforms or point-of-care instruments to analyze patient samples and deliver quick, accurate results. What sets QuidelOrtho apart is its long history and the combination of Quidel’s and Ortho’s expertise into a broad portfolio, with a global reach and long-term contracts with healthcare providers. The company’s goal is to improve diagnostic accuracy and efficiency to support better patient outcomes and broad access to essential diagnostic solutions.
Work here?Claim your company
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
San Diego, CA
Founded
1937
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$3.4B
Above
Industry Average
Funded Over
1 Rounds
Law firm Levi & Korsinsky is investigating QuidelOrtho (NASDAQ: QDEL) for potential securities law violations after the company's shares fell about 14%. The drop followed QuidelOrtho's third-quarter 2026 results, which included a narrowed full-year revenue outlook and a restructuring programme. Company disclosures describe the programme as about $100 million and running through 2027. The investigation examines whether QuidelOrtho made misleading statements about its near-term outlook, including liquidity and revenue expectations. In an August 7, 2026 quarterly report, the company said its cash and credit facility would fund its needs for at least 12 months. That report showed negative operating cash flow of $143.6 million and $426.5 million of remaining revolver availability.
QuidelOrtho shares have fallen 55.4% since the start of the year, including dividends, even as the diagnostics maker narrowed its loss. The stock now trades at $12.84, down from $28.56 on January 1, 2026. Third-quarter revenue fell from $699.9 million to $618.9 million, and the company still reported a loss. Falling COVID demand and high debt weighed on sentiment. QuidelOrtho is exploring a $1.5 billion sale of its point of care unit, with proceeds framed as a way to cut debt. Analyst views split widely. The bullish case put fair value at $40.33, while the bearish case set it at $26.
QuidelOrtho Corporation, a San Diego-based medical diagnostics company, reported a third-quarter loss of $53.8 million on Tuesday. That works out to a loss of 78 cents per share. Adjusted for one-time gains and costs, earnings were 31 cents per share. Revenue for the period was $618.9 million. For the full year, the company expects earnings of 65 cents to 70 cents per share and revenue of $2.52 billion to $2.54 billion.
QuidelOrtho reported third-quarter 2026 revenue of $619 million, down 12% from a year earlier. The San Diego diagnostics company cited lower sales in China, after changes to In Vitro Diagnostics pricing, and a softer respiratory season. Net loss was $54 million, and adjusted EBITDA was $148 million. Point of Care revenue fell 27% to $120 million, while Labs revenue fell 6% to $353 million. Outside China, Labs revenue grew 3%. The company launched a cost transformation and restructuring program that it expects to save over $80 million a year in 2027. It will record about $30 million to $35 million in one-time charges in the fourth quarter. It will also reorganise around two businesses, Core Diagnostics and Point of Care Diagnostics.
QuidelOrtho launches VITROS 450 chemistry system. * November 02, 2026 QuidelOrtho has launched the VITROS 450 chemistry system, a next-generation analyser designed to empower low-volume and community-based laboratories with high-quality, reliable results. Compact yet powerful, the VITROS 450 System enables laboratories to do more with less - supporting patient care in rural clinics, urban satellite laboratories and network facilities. It offers intuitive design and proven technology, making it ideal for laboratories seeking quality without compromise. This launch marks an important milestone in advancing diagnostic access and quality across diverse healthcare environments. The VITROS 450 System is now available in key markets around the world, including China, Asia-Pacific, Europe, Middle East and Africa and Latin America. Waterless operation eliminates the need for plumbing or drains and simplifies maintenance. The system keeps testing simple, consistent and dependable regardless of who is at the bench, supporting teams with diverse experience levels. The compact footprint suits laboratories with limited space. Waterless operation and the overall system design helps reduce operational waste and energy use.
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
San Diego, CA
Founded
1937
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs